Abstract:Hexameric structure formation through packing of three C-terminal helices and an N-terminal trimeric coiled-coil core has been proposed as a general mechanism of class I enveloped virus entry. In this process, the C-terminal helical repeat (HR2) region of viral membrane fusion proteins becomes transiently exposed and accessible to N-terminal helical repeat (HR1) trimer-based fusion inhibitors. Herein, we describe a mimetic of the HIV-1 gp41 HR1 trimer, N3G, as a promising therapeutic against HIV-1 infection. Surprisingly, we found that in addition to protection against HIV-1 infection, N3G was also highly effective in inhibiting infection of human β-coronaviruses, including MERS-CoV, HCoV-OC43, and SARS-CoV-2, possibly by binding the HR2 region in the spike protein of β-coronaviruses to block their hexameric structure formation. These studies demonstrate the potential utility of anti-HIV-1 HR1 peptides in inhibiting human β-coronavirus infection. Moreover, this strategy could be extended to the design of broad-spectrum antivirals based on the supercoiling structure of peptides.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.1c00258?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00258</a>.Summary of the SVA results; biophysical properties of the designed peptides; HPLC method used for the purification of peptide compounds; HPLC method used for the analysis of peptide compounds; evidence that both N3G and EK1 are effective against SARS-CoV-2 infection; CD spectra of the complex formed between N3G and SARS-CoV-2 HR2P; sequence similarity between the HR2 domain of MERS-CoV, OC43, or SARS-CoV-2 and that of HIV-1; inhibitory activity of peptides on pseudotyped SARS-CoV infection; and MALDI-TOF-MS and analytical HPLC of designed peptides (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00258/suppl_file/jm1c00258_si_002.pdf">PDF</a>)Molecular formula strings of all compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00258/suppl_file/jm1c00258_si_003.csv">CSV</a>)This article has not yet been cited by other publications.

Antiviral Activity of Dual-acting Hydrocarbon-stapled Peptides Against HIV-1 Predominantly Circulating in China.

Design and Biological Evaluation of M-Xylene Thioether-Stapled Short Helical Peptides Targeting the HIV-1 Gp41 Hexameric Coiled-Coil Fusion Complex.

Rational Design of Sulfonyl-?-AApeptides as Highly Potent HIV-1 Fusion Inhibitors with Broad-Spectrum Activity

Rational Design of Peptides with Anti-Hcv/Hiv Activities and Enhanced Specificity

Design, synthesis, and antiviral activity of phenylalanine derivatives as HIV-1 capsid inhibitors

Design of the artificial N-peptides with coiled-coil trimer structure against HIV-1 based on the SWISS MODEL and HDOCK-aided strategy

Short Communication: in VitroSynergy Between Peptides or Neutralizing Antibodies Targeting the N- and C-Terminal Heptad Repeats of HIV Type 1 Gp41

Design, Synthesis and Activity Evaluation of Novel Peptide Fusion Inhibitors Targeting HIV-1 Gp41

Supercoiling Structure-Based Design of a Trimeric Coiled-Coil Peptide with High Potency against HIV-1 and Human β-Coronavirus Infection

A “Two-Birds-One-Stone” Approach toward the Design of Bifunctional Human Immunodeficiency Virus Type 1 Entry Inhibitors Targeting the CCR5 Coreceptor and gp41 N-Terminal Heptad Repeat Region

Glycan-Modified Peptides for Dual Inhibition of Human Immunodeficiency Virus Entry into Dendritic Cells and T Cells

Design of artificial α-helical peptides targeting both gp41 deep pocket and subpocket as potent HIV-1 fusion inhibitors

Discovery of a Double-Stapled Short Peptide as a Long-Acting HIV-1 Inactivator with Potential for Oral Bioavailability

Design of Vif-Derived Peptide Inhibitors with Anti-HIV-1 Activity by Interrupting Vif-CBFβ Interaction

Design, Synthesis, and Biological Evaluation of Highly Potent Small Molecule–Peptide Conjugates As New HIV-1 Fusion Inhibitors

An Artificial Peptide-Based Bifunctional HIV-1 Entry Inhibitor That Interferes with Viral Glycoprotein-41 Six-Helix Bundle Formation and Antagonizes CCR5 on the Host Cell Membrane

Design of Biphenyl-Substituted Diarylpyrimidines with a Cyanomethyl Linker as HIV-1 NNRTIs via a Molecular Hybridization Strategy.

Novel Recombinant Engineered Gp41 N-terminal Heptad Repeat Trimers and Their Potential As Anti-Hiv-1 Therapeutics or Microbicides.

Multitargeted Drug Design Strategy for Discovery of Short-Peptide-based HIV-1 Entry Inhibitors with High Potency

Design of Artificial C-Peptides as Potential Anti-HIV-1 Inhibitors Based on 6-HB Formation Mechanism

Artificial Peptides Conjugated with Cholesterol and Pocket-Specific Small Molecules Potently Inhibit Infection by Laboratory-Adapted and Primary HIV-1 Isolates and Enfuvirtide-Resistant HIV-1 Strains.